Johnson & Johnson's oncology franchise is gaining in prominence, narrowing the gap in the first quarter with the company's top-selling immunology franchise. Global oncology sales grew 45% to $2.31bn in the quarter, powered by strong growth of Darzalex (daratumumab), Imbruvica (ibrutinib) and Zytiga (abiraterone). Meanwhile, growth in immunology is slowing, with worldwide sales growing 3.8% to $3.04bn.
Oncology is now solidly the second top pharma franchise at J&J, outpacing cardiovascular/metabolic, neuroscience and infectious disease. J&J reported first-quarter...








